Mortality trends over five decades in adult transgender people receiving hormone treatment: a report from the Amsterdam cohort of gender dysphoria.

@article{deBlok2021MortalityTO,
  title={Mortality trends over five decades in adult transgender people receiving hormone treatment: a report from the Amsterdam cohort of gender dysphoria.},
  author={Christel JM. de Blok and Chantal Maria Wiepjes and Daan M. van Velzen and Annemieke S Staphorsius and Nienke M Nota and Louis J Gooren and Baudewijntje P. C. Kreukels and Martin den Heijer},
  journal={The lancet. Diabetes \& endocrinology},
  year={2021}
}

Mortality risk in transgender people is twice as high as in cisgender people, data show

The study included 2927 transgender women and 1641 transgender men who visited the gender identity clinic of Amsterdam University Medical Centre in the Netherlands and received hormone treatment from 1972 to 2018, finding that the average age at the start of hormone treatment was 30 in transgenderWomen and 23 in transgender men.

What Cardiothoracic Radiologists Should Know About Imaging in Transgender Patients

Transgender and gender diverse (TGD) individuals may undergo a wide range of care during gender transition including mental health counseling, gender-affirming hormonal therapy, and various

Transgender Medicine and Risk of Venous Thromboembolism.

An overview of the currently available medical therapies in transgender medicine is provided, and the associated increased risk of venous thromboembolism into perspective is put into perspective.

Gender medicine: effects of sex and gender on cardiovascular disease manifestation and outcomes

Despite a growing body of evidence, the distinct contributions of biological sex and the sociocultural dimension of gender to the manifestations and outcomes of ischaemic heart disease and heart

Estrogen May Enhance Toll-Like Receptor 4-Induced Inflammatory Pathways in People With HIV: Implications for Transgender Women on Hormone Therapy

While estrogen exposure alone induced mild changes in immune activation, LPS-induced TLR4 activation was elevated with estrogen in cisgender men with HIV, increasing monocyte activation and inflammatory cytokine production (IL-6, TNF-α).

Ensuring equitable, inclusive and meaningful gender identity- and sexual orientation-related data collection in the healthcare sector: insights from a critical, pragmatic systematic review of the literature

Abstract In several countries, no gender identity- and sexual orientation-related data is routinely collected, if not for specific health or administrative/social purposes. Implementing and ensuring

Gender-affirming Hormone Therapy and Risk of Diabetes in Transgender Persons

  • V. Tangpricha
  • Medicine
    The Journal of clinical endocrinology and metabolism
  • 2022
This study highlights the need to understand more fully the role of phosphorous in the development of insulin resistance and its role in the immune response.

Women's Health Issues in Thrombosis and Haemostasis.

In the last couple of years sex specific health issues have continually been gaining attraction by physicians of different medical specialities and many aspects concerning risk factors, clinical presentation and management of thromboembolic disease and bleeding disorders also display sex differences.

Care of Transgender Patients: A General Practice Quality Improvement Approach

This quality improvement project aimed to interrogate and audit the data of trans and gender minority patients in one primary care population in England, finding inconsistency between multiple UK gender identity clinics’ (GIC) individual recommended schedules of care and between specialty guidelines.

References

SHOWING 1-10 OF 26 REFERENCES

A long-term follow-up study of mortality in transsexuals receiving treatment with cross-sex hormones.

The increased mortality in hormone-treated MtF transsexuals was mainly due to non-hormone-related causes, but ethinyl estradiol may increase the risk of cardiovascular death, and use of testosterone in doses used for hypogonadal men seemed safe.

The occurrence of benign brain tumours in transgender individuals during cross-sex hormone treatment

It is concluded that cross-sex hormone treatment is associated with a higher risk of meningiomas and prolactinomas in transwomen, which may be linked to cyproterone acetate usage, and somatotrophinoma in transmen.

Cancer in Transgender People: Evidence and Methodological Considerations.

The goals of this article are to summarize the evidence on factors that may differentially affect cancer risk in transgender people, assess the relevant cancer surveillance and epidemiologic data available to date, and offer an overview of possible methodological considerations for future studies investigating cancer incidence and mortality in this population.

Mortality Among Veterans with Transgender-Related Diagnoses in the Veterans Health Administration, FY2000-2009.

The crude suicide rate among veterans with transgender-related ICD-9-CM diagnoses is higher than in the general population, and they may be dying by suicide at younger ages than their veteran peers without transgender- related I CD- 9- CM diagnoses.

Incidence of breast cancer in a cohort of 5,135 transgender veterans

It appears that TG veterans do not display an increase in breast cancer incidence, consistent with European studies of longer duration that conclude that CSH treatment in gender dysphoric patients of either birth sex does not result in a greater incidence than the general population.

Cardiovascular Disease Among Transgender Adults Receiving Hormone Therapy

Cross-sex hormone therapy (CSHT), particularly with testosterone, is associated with worsening cardiovascular risk factors in transgender men but not with increases in cardiovascular morbidity or mortality, and the literature regarding the association between CSHT and CVD in transgender adults is summarized.

Prevalence of gender identity disorder and suicide risk among transgender veterans utilizing veterans health administration care.

The prevalence and incidence of gender identity disorder diagnoses among veterans in the Veterans Health Administration (VHA) health care system and suicide risk among veterans with a GID diagnosis were estimated and examined.